Literature DB >> 14620931

Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells.

Akira Takahara1, Shin-ichi Fujita, Keiko Moki, Yukitsugu Ono, Hajime Koganei, Satoshi Iwayama, Hiroshi Yamamoto.   

Abstract

Although the anti-sympathetic mechanisms of the antihypertensive drug cilnidipine have been analyzed in neuronal cells derived from rodents, there is little information regarding the effects of cilnidipine in human neuronal cells. We investigated the effects of cilnidipine on N-type Ca2+ channels in IMR-32 human neuroblastoma cells using fura-2-based microfluorimetry. The ratio of the intensities of the emitted fluorescence at an excitation wavelength of 340 nm to that at 380 nm was calibrated to estimate the intracellular concentration of Ca2+. Stimulation of IMR-32 cells by 40 mmol/l KCl immediately increased the intensities ratio. In the presence of 10 micromol/l of nifedipine to block L-type Ca2+ channels, omega-conotoxin GVIA, a selective N-type Ca2+ channel blocker, in a concentration of 1 micromol/l suppressed the elevation of the intensities ratio induced by 40 mmol/l KCl. Similarly, cilnidipine in a concentration of 10 micromo/l suppressed the elevation of the ratio induced by 40 mmol/l KCl, and this suppression was effectively inhibited after the treatment with omega-conotoxin GVIA. These results suggest that cilnidipine potentially inhibits N-type Ca2+ channels in human neuronal cells and might be applied as a prospective therapeutic tool to provide neuronal protection as well as its antihypertensive effects and anti-sympathetic actions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14620931     DOI: 10.1291/hypres.26.743

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Molecular modelling and QSAR analysis of some structurally diverse N-type calcium channel blockers.

Authors:  Jignesh Mungalpara; Ashish Pandey; Vaibhav Jain; C Gopi Mohan
Journal:  J Mol Model       Date:  2009-10-04       Impact factor: 1.810

Review 2.  The fourth-generation Calcium channel blocker: cilnidipine.

Authors:  K Sarat Chandra; G Ramesh
Journal:  Indian Heart J       Date:  2013-12

3.  Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis.

Authors:  Takaaki Nakatsu; Shinji Toyonaga; Keiichi Mashima; Yoko Yuki; Aya Nishitani; Hiroko Ogawa; Toru Miyoshi; Satoshi Hirohata; Reishi Izumi; Shozo Kusachi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Authors:  Bai Lei; Daisuke Nakano; Yoshihide Fujisawa; Ya Liu; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Katsuhiko Asanuma; Yasuhiko Tomino; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2012-07-21       Impact factor: 3.337

5.  Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study.

Authors:  Prabhakar Adake; H S Somashekar; P K Mohammed Rafeeq; Dilshad Umar; Bahija Basheer; Kusai Baroudi
Journal:  J Adv Pharm Technol Res       Date:  2015 Apr-Jun

6.  A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.

Authors:  Rugmani Padmanabhan Iyer; Merry L Lindsey; Robert J Chilton
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.